Dataset_NephroLongCovid_figshare

Our aim was to correctly identify the ME/CFS patients, including an initial rule-in screening by investigating other possible causes (pulmonary/cardiac/endocrine, etc.). In 7 cases we performed plasmapheresis (PE) with repeated autoantibody measurements. In addition, according to literature references, psychometric follow-up assessments were performed to monitor clinical outcomes: with the ISI (insomnia), FSS (fatigue), HADS (depression and anxiety) and EQ-5D-5L (quality of life) questionnaires. Patients who met the inclusion criteria received 4 PE sessions on days 1, 5, 30 and 60 and low-dose intravenous immunoglobulin (IVIG) therapy after each treatment. Psychometric assessment was performed before the first PE, 2 weeks after the second PE and 2 weeks after the last PE. All 4 antibodies were measured twice per patient over the course of the study at standardized sampling times: baseline before the start of PE and 2 weeks after the last PE.